Experiment 635224
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | GULICK,RM: MC AULIFFE,V: HOLDEN-WILTSE,J: CRUMPACKER,C: LIEBES,L: STEIN,DS: MEEHAN,P: HUSSEY,S: FORCHT,J: VALENTINE,FT:. (1999). PHASE I STUDIES OF HYPERICIN, THE ACTIVE COMPOUND IN ST. JOHN'S WORT, AS AN ANTIRETROVIRAL AGENT IN HIV-INFECTED ADULTS. AIDS CLINICAL TRIALS GROUP PROTOCOLS 150 AND 258.. 130() |
| Amount utilized | |
| Compound isolated | |
| Disease | THE SAFETY AND ANTIRETROVIAL ACTIVITES OF HYPERICIN IN HIV-INFECTED PATIENTS WERE STUDIED. INTRAVENOUS HYPERCIN, 0.25 OR 0.5 MG/KG TWICE WEEKLY OR 0.25 MG/KG 3 TIMES WEEKLY OR ORAL HYPERICIN 0.5 MG/KG DAILY. SAFETY WAS ASSESSED IN WEEKLY VISITS. ANTIRETROVIRAL ACTIVITY WAS ASSESS BY CHANGES IN HIV P24 ANGIGEN LEVEL, HIV TITER, HIV RNA COPIES, AND CD4 CELL COUNTS. OF THE 30 PATIENTS 16 DISCONTINUED TREATMENT EARLY BECAUSE OF TOXIC EFFECTS. SEVERE PHOTOTOXICITY WAS OBSERVED IN 11 OF 23. VIROLOGIC MARKERS AND CD4 CELLS COUNT DID NOT SIGNIFICANTLY CHANGE. HYPERICIN CAUSED SIGNIFICANT PHOTOTOXICITY AND HAS NO ANTIRETROVIRAL ACTIVITY IN THE LIMITED NUMBER OF PATIENTS. |
| Dose amount | VAR |
| Number | 1 |
| Qualitative result | INACTIVE |
| Animal | HUMAN ADULT |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |